Comparing 3 drug combos for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with stomach or gastroesophageal junction cancer that is HER2-negative and has spread to other parts of the body
- You have not had previous treatment for advanced cancer, or it has been at least 6 months since completing any chemotherapy after surgery and you have not had any cancer treatment in the past 6 months
- You are in generally good health (able to do daily activities with minimal help)
- Your organs (like liver, kidneys, and bone marrow) are working well enough based on blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests three drugs together—tafolecimab, sintilimab, and chemotherapy (SOX)—to treat advanced stomach cancer that cannot be removed by surgery. The drugs work in different ways to help your immune system fight cancer cells.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Gastric (Stomach) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.